Advertisement

Cancer Causes & Control

, Volume 30, Issue 12, pp 1351–1363 | Cite as

Economics of public health programs for underserved populations: a review of economic analysis of the National Breast and Cervical Cancer Early Detection Program

  • Jaya S. KhushalaniEmail author
  • Justin G. Trogdon
  • Donatus U. Ekwueme
  • K. Robin Yabroff
Original Paper
  • 100 Downloads

Abstract

Purpose

The purpose of this paper is to provide a brief overview of economic analysis methods used in estimating the costs and benefits of public health programs and systematically review the application of these methods to the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).

Methods

Published literature on economic analyses of the NBCCEDP was systematically reviewed. The Consensus on Health Economic Criteria checklist was used to assess methodological quality of the included studies.

Results

Methods available for economic analysis of public health programs include program cost, cost-effectiveness, cost–utility, cost–benefit analysis, and budget impact analysis. Of these, program cost analysis, cost-effectiveness analysis, and cost–utility analysis have been applied to the NBCCEDP in previously published literature.

Conclusion

While there have been multiple program cost analyses, there are relatively fewer cost-effectiveness and cost–utility studies and no cost–benefit and budget impact analysis studies to evaluate the NBCCEDP. Addressing these gaps will inform implementation of effective public health programs with equitable resource allocation to all population subgroups.

Keywords

Economic analysis Cost-effectiveness Cancer screening Public health Underserved 

Notes

Acknowledgments

The authors sincerely thank Dr. Amy DeGroff, Health Scientist, Division of Cancer Prevention and Control, CDC, for her invaluable suggestions in early version of this manuscript.

References

  1. 1.
    Napper M, Newland J (2003) Health economics information resources: a self-study course. US National Library of Medicine, BethesdaGoogle Scholar
  2. 2.
    Yabroff KR et al (2011) Economic Burden of Cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Prev Biomark 20(10):2006–2014CrossRefGoogle Scholar
  3. 3.
    Zheng Z et al (2016) Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. JNCI.  https://doi.org/10.1111/eip.12846 CrossRefPubMedGoogle Scholar
  4. 4.
    Sanchez E (2007) Preventive care: a national profile on use, disparities, and health benefits. Partnership for Prevention, Washington, DCGoogle Scholar
  5. 5.
    Winn AN et al (2016) Cost-utility analysis of cancer prevention, treatment, and control: a systematic review. Am J Prev Med 50(2):241–248CrossRefGoogle Scholar
  6. 6.
    American Cancer Society Cancer Action Network (2009) Cancer disparities a chartbook. American Cancer Society, Washington DCGoogle Scholar
  7. 7.
    Smedley BD, Haynes MA (1999) The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. National Academies Press, Washington DCGoogle Scholar
  8. 8.
    Drummond MF et al (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, OxfordGoogle Scholar
  9. 9.
    Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program (NBCCEDP). 2017 February 2, 2018 [cited 2018 February 12]; https://www.cdc.gov/cancer/nbccedp/index.htm
  10. 10.
    Jo C (2014) Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol 20(4):327CrossRefGoogle Scholar
  11. 11.
    Van den Hout W (2010) The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 69(Suppl 1):i89–i91CrossRefGoogle Scholar
  12. 12.
    Yabroff KR et al (2008) Estimates and projections of value of life lost from cancer deaths in the United States. JNCI 100(24):1755–1762CrossRefGoogle Scholar
  13. 13.
    Birch S, Gafni A (2003) Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. Health Policy 64(2):207–219CrossRefGoogle Scholar
  14. 14.
    Haddix AC, Teutsch SM, Corso PS (2003) Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press, OxfordGoogle Scholar
  15. 15.
    Ekwueme DU et al (2014) Cost of services provided by the National Breast and Cervical Cancer Early Detection Program. Cancer 120(S16):2604–2611CrossRefGoogle Scholar
  16. 16.
    Tangka FK et al (2013) Clinical costs of colorectal cancer screening in 5 federally funded demonstration programs. Cancer 119(S15):2863–2869CrossRefGoogle Scholar
  17. 17.
    Finkelstein EA, Wittenborn JS, Farris RP (2004) Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN. J Women’s Health 13(5):625–633CrossRefGoogle Scholar
  18. 18.
    Gorsky RD (1996) A method to measure the costs of counseling for HIV prevention. Public Health Rep 111(Suppl 1):115PubMedPubMedCentralGoogle Scholar
  19. 19.
    Shih YCT, Halpern MT (2008) Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA: Cancer J Clin 58(4):231–244Google Scholar
  20. 20.
    Lairson DR et al (2014) Cervical cancer screening with AMIGAS: a cost-effectiveness analysis. Am J Prev Med 46(6):617–623CrossRefGoogle Scholar
  21. 21.
    Lich KH et al (2017) Cost-effectiveness analysis of four simulated colorectal cancer screening interventions, North Carolina. Prev Chronic Dis 14(160158):E18Google Scholar
  22. 22.
    Neumann PJ, Greenberg D (2009) Is the United States ready for QALYs? Health Aff 28(5):1366–1371CrossRefGoogle Scholar
  23. 23.
    Torrance GW (1997) Preferences for health outcomes and cost-utility analysis. Am J Manag Care 3(Suppl 1):S8–S20PubMedGoogle Scholar
  24. 24.
    Weinstein MC, Torrance G, McGuire A (2009) QALYs: the basics. Value Health 12:S5–S9CrossRefGoogle Scholar
  25. 25.
    Krahn MD et al (1994) Screening for prostate cancer: a decision analytic view. JAMA 272(10):773–780CrossRefGoogle Scholar
  26. 26.
    Partnership to Improve Patient Care. Measuring value in medicine: uses and misuses of the QALY. [cited 2019; http://www.pipcpatients.org/uploads/1/2/9/0/12902828/pipc_white_paper_-_measuring_value_in_medicine_-_uses_and_misuses_of_the_qaly.pdf
  27. 27.
    Donaldson C (1998) The (Near) equivalence of cost—effectiveness and cost-benefit analyses. Pharmacoeconomics 13(4):389–396CrossRefGoogle Scholar
  28. 28.
    Zarnke KB, Levine MA, O’Brien BJ (1997) Cost-benefit analyses in the health-care literature: don’t judge a study by its label. J Clin Epidemiol 50(7):813–822CrossRefGoogle Scholar
  29. 29.
    Fric P et al (1994) An adapted program of colorectal cancer screening–7 years experience and cost-benefit analysis. Hepatogastroenterology 41(5):413–416PubMedGoogle Scholar
  30. 30.
    Adler MD, Posner EA (1999) Rethinking cost-benefit analysis. Yale Law J 109(2):165–247CrossRefGoogle Scholar
  31. 31.
    Kim B et al (2017) Budget impact analysis of against colorectal cancer in our neighborhoods (ACCION): a successful community-based colorectal cancer screening program for a medically underserved minority population. Value Health 20:809–818CrossRefGoogle Scholar
  32. 32.
    Evers S et al (2005) Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care 21(2):240–245CrossRefGoogle Scholar
  33. 33.
    Demarré L et al (2015) The cost of prevention and treatment of pressure ulcers: a systematic review. Int J Nursing Stud 52(11):1754–1774CrossRefGoogle Scholar
  34. 34.
    The Cochrane Collaboration (2011) Cochrane handbook for systematic reviews of interventions: version 5.1. 0Google Scholar
  35. 35.
    Ekwueme DU et al (2008) Cost analysis of the national breast and cervical cancer early detection program. Cancer 112(3):626–635CrossRefGoogle Scholar
  36. 36.
    Subramanian S et al (2008) Identifying and controlling for program-level differences in comparative cost analysis: lessons from the economic evaluation of the National Breast and Cervical Cancer Early Detection Program. Eval Progr Plan 31(2):136–144CrossRefGoogle Scholar
  37. 37.
    Subramanian S et al (2019) Awardee-specific economic costs of providing cancer screening and health promotional services to medically underserved women eligible in the National Breast and Cervical Cancer Early Detection Program. Cancer Causes Control 30:1–8CrossRefGoogle Scholar
  38. 38.
    Trogdon JG et al (2019) The effect of delivery structure on costs, screening and health promotional services in state level National Breast and Cervical Cancer Early Detection Programs. Cancer Causes Control 30:1–6CrossRefGoogle Scholar
  39. 39.
    Ekwueme DU et al (2008) Estimating personal costs incurred by a woman participating in mammography screening in the National Breast and Cervical Cancer Early Detection Program. Cancer 113(3):592–601CrossRefGoogle Scholar
  40. 40.
    Rim SH et al (2019) Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program. Cancer Causes Control 30:1–8CrossRefGoogle Scholar
  41. 41.
    Allaire BT et al (2019) Cost-effectiveness of patient navigation for breast cancer screening in the National Breast and Cervical Cancer Early Detection Program. Cancer Causes Control 30(9):923–929CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply  2019

Authors and Affiliations

  1. 1.Division of Cancer Prevention and ControlCenter for Disease Control and PreventionAtlantaUSA
  2. 2.Department of Health Policy and Management, Gillings School of Global Public Health and Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel HillUSA
  3. 3.Surveillance and Health Services ResearchAmerican Cancer SocietyAtlantaUSA

Personalised recommendations